DRUG-DRUG INTERACTION (DDI) STUDY BETWEEN THE INVESTIGATIONAL NAE INHIBITOR PEVONEDISTAT (TAK-924) AND FLUCONAZOLE OR ITRACONAZOLE IN PATIENTS WITH ADVANCED SOLID TUMORS.

被引:0
|
作者
Faessel, H. M. [1 ]
Harvey, R. D. [2 ]
Lockhart, A. C. [3 ]
Bauer, T. M. [4 ]
Wang, L. [1 ]
Sedarati, F. [1 ]
Santillana, S. [1 ]
Nemunaitis, J. J. [5 ]
机构
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[4] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[5] Mary Crowley Canc Res Ctr, Dallas, TX USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
PII-084
引用
收藏
页码:S97 / S97
页数:1
相关论文
共 50 条
  • [41] A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
    Olszanski, Anthony J.
    Middleton, Mark R.
    Bahleda, Rastilav
    Heist, Rebecca Suk
    Rangachari, Lakshmi
    Zhou, Xiaofei
    Bozon, Viviana
    Kneissl, Michelle
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.
    Shimizu, Toshio
    Doi, Toshihiko
    Kondo, Shunsuke
    Takahashi, Hideaki
    Yamamoto, Noboru
    Sheldon-Waniga, Emily
    Zhou, Xiaofei
    Bahamon, Brittany
    Li, Hongmei
    Kuboki, Yasutoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study
    Moreno, Irene
    Hernandez, Tatiana
    Calvo, Emiliano
    Fudio, Salvador
    Kahatt, Carmen
    Fernandez, Cristian
    Iglesias, Jorge Luis
    Corral, Gema
    Perez-Ramos, Laura
    Montilla, Lola
    Zeaiter, Ali
    Lubomirov, Rubin
    PHARMACEUTICALS, 2024, 17 (02)
  • [44] EVALUATION OF PHARMACOKINETIC DRUG-DRUG INTERACTION (DDI) BETWEEN BMS-791325, AN NS5B NON-NUCLEOTIDE POLYMERASE INHIBITOR, DACLATASVIR AND ASUNAPREVIR IN TRIPLE COMBINATION IN HCV GENOTYPE 1-INFECTED PATIENTS
    Wang, X.
    Li, W.
    Huang, S. -P.
    He, B.
    Chung, E.
    Griffies, A.
    Cooney, E.
    Hughes, E.
    Kandoussi, H.
    Sims, K.
    Gardiner, D.
    Bertz, R.
    Eley, T.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S184 - S184
  • [45] Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis
    Olszanski, A. J.
    Gonzalez, R.
    Corrie, P.
    Pavlick, A. C.
    Middleton, M.
    Lorigan, P.
    Plummer, R.
    Skaria, S.
    Herbert, C.
    Gore, M.
    Agarwala, S.
    Daud, A.
    Zhang, S.
    Bahamon, B.
    Rangachari, L.
    Hoberman, E.
    Kneissl, M.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer
    Feld, R.
    Woo, M. M.
    Shepherd, F. A.
    Leighl, N. B.
    Elshtein, R.
    Hengelage, T.
    Hirawat, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK plus advanced tumors
    Hurtado, Felipe K.
    de Braud, Filippo
    De Castro Carpeno, Javier
    de Miguel Luken, Maria Jose
    Wang, Ding
    Scott, Jeffrey
    Lau, Yvonne Y.
    McCulloch, Tracey
    Mau-Sorensen, Morten
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (04) : 475 - 486
  • [48] First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.
    Sosman, J. A.
    Adjei, A. A.
    LoRusso, P.
    Michael, S. A.
    Dy, G. K.
    Bowditch, A.
    Chmielowski, B.
    Lee, S.
    Walker, R. M.
    Faucette, S.
    Izmailova, E. S.
    Bozon, V.
    Ribas, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Phase 1 study of investigational oral mTORC1/2 inhibitor TAK-228 (MLN0128): Tolerability and food effects of a milled formulation in patients (pts) with advanced solid tumors
    Moore, K. N.
    Bauer, T. M.
    Falchook, G.
    Patel, C.
    Neuwirth, R.
    Enke, A.
    Zohren, F.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer
    DeJonge, M.
    Woo, M. M.
    Van der Biessen, D.
    Hamberg, P.
    Sharma, S.
    Chen, L. C.
    Myke, N.
    Zhao, L.
    Hirawat, S.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)